Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246739 | 0.79 | HSP90AA1 (0.56) | KEAP1MLYCDMEN1KMT2ALMNA | |
| SCHEMBL2579068 | 0.79 | KEAP1 (0.56) | KEAP1HSPA5TSHRLMNA | |
| SCHEMBL4811057 | 0.77 | LMNA (0.65) | KEAP1HSPA5TSHRKMT2ALMNA | |
| SCHEMBL8429380 | 0.75 | MLYCD (0.53) | MLYCDTSHRMEN1KMT2ATDP1 | |
| SCHEMBL12982112 | 0.75 | MLYCD (0.53) | MLYCDTSHRMEN1KMT2AHDAC1 | |
| SCHEMBL6248551 | 0.75 | TSHR (0.69) | KEAP1HSPA5TSHRLMNASLC7A5 | |
| SCHEMBL6489038 | 0.75 | MAPT (0.51) | TSHRMEN1KMT2ATDP1 | |
| SCHEMBL2651766 | 0.74 | MLYCD (0.49) | MLYCDTSHRKMT2ALMNAHDAC1 | |
| SCHEMBL28777 | 0.74 | MLYCD (0.54) | MLYCDTSHRTRPM8MEN1KMT2A | |
| SCHEMBL9776607 | 0.74 | KEAP1 (0.86) | KEAP1HSPA5TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414072-B2 | Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| US-7250522-B2 | Method for selective preparation of aryl 5-thio-β-D-aldohexopyranosides | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20050256317-A1 | Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-22 | — | — | US | disclosed |
| EP-1541578-A1 | PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-BETA-D-ALDOHEXOPYRANOSIDES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1528066-A1 | ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256317-A1 | Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides | ALDOA, DERA, AKR1D1 | KEAP1 1983/4885MLYCD 2316/4885HSPA5 3012/4885 |
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | SLC5A2, SLC5A1, UGGT1 | KEAP1 238/4885MLYCD 1984/4885HSPA5 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.